Monopar Therapeutics Company Insiders
MNPR Stock | USD 19.86 0.15 0.76% |
Monopar Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Monopar Therapeutics suggests that virtually all insiders are extremely bullish. Monopar Therapeutics employs about 9 people. The company is managed by 5 executives with a total tenure of roughly 21 years, averaging almost 4.0 years of service per executive, having 1.8 employees per reported executive.
Monopar Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-10-28 | Karthik Radhakrishnan | Acquired 1550 @ 16.25 | View | ||
2024-06-20 | Andrew Cittadine | Acquired 4101 @ 3.7 | View | ||
2024-06-17 | Andrew Cittadine | Acquired 2400 @ 4.5 | View | ||
2024-06-13 | Andrew Cittadine | Acquired 2400 @ 4.55 | View | ||
2024-06-03 | Andrew Cittadine | Acquired 2400 @ 3.8 | View | ||
2024-05-31 | Andrew Cittadine | Acquired 2400 @ 3.2 | View | ||
2024-05-29 | Andrew Cittadine | Acquired 2400 @ 3.2 | View |
Monitoring Monopar Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Monopar |
Monopar Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Monopar Therapeutics' future performance. Based on our forecasts, it is anticipated that Monopar will maintain a workforce of slightly above 9 employees by December 2024.Monopar Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5345) % which means that it has lost $0.5345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0231) %, meaning that it created substantial loss on money invested by shareholders. Monopar Therapeutics' management efficiency ratios could be used to measure how well Monopar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -1.2. In addition to that, Return On Capital Employed is likely to drop to -1.66. At this time, Monopar Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/22/2024, Total Current Assets is likely to grow to about 11.2 M, while Non Current Assets Total are likely to drop slightly above 12 K.As of 11/22/2024, Common Stock Shares Outstanding is likely to drop to about 12.7 M. In addition to that, Net Loss is likely to drop to about (8.6 M)
Monopar Therapeutics Workforce Comparison
Monopar Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 612. Monopar Therapeutics claims roughly 9.0 in number of employees contributing just under 2% to equities under Health Care industry.
Monopar Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monopar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monopar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Monopar Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.75 | 3 | 4 | 131,686 | 9,139 |
2024-06-01 | 2.1429 | 15 | 7 | 280,893 | 141,086 |
2024-03-01 | 0.6 | 6 | 10 | 61,337 | 68,521 |
2023-12-01 | 0.7 | 7 | 10 | 53,515 | 69,155 |
2023-09-01 | 0.7 | 7 | 10 | 53,515 | 66,755 |
2023-06-01 | 0.7 | 7 | 10 | 73,862 | 93,292 |
2023-03-01 | 1.7143 | 24 | 14 | 900,073 | 51,237 |
2022-12-01 | 0.9 | 9 | 10 | 50,530 | 42,764 |
2022-09-01 | 0.7 | 7 | 10 | 34,476 | 41,497 |
2022-06-01 | 0.75 | 6 | 8 | 44,231 | 53,478 |
2022-03-01 | 1.9286 | 27 | 14 | 963,944 | 29,645 |
2021-12-01 | 0.7 | 7 | 10 | 9,772 | 12,193 |
2021-09-01 | 0.8 | 8 | 10 | 101,272 | 11,821 |
2021-06-01 | 0.8182 | 9 | 11 | 116,545 | 90,620 |
2021-03-01 | 1.4667 | 22 | 15 | 294,485 | 141,398 |
2020-12-01 | 1.0 | 4 | 4 | 1,288 | 1,288 |
2020-09-01 | 1.0 | 4 | 4 | 1,288 | 1,288 |
2020-06-01 | 1.0 | 4 | 4 | 1,292 | 1,292 |
2020-03-01 | 4.75 | 19 | 4 | 239,120 | 1,288 |
2019-12-01 | 3.5 | 7 | 2 | 769,072 | 18,433 |
Monopar Therapeutics Notable Stakeholders
A Monopar Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Monopar Therapeutics often face trade-offs trying to please all of them. Monopar Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Monopar Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Starr | CoFounder Board | Profile | |
Kim CPA | Secretary, CFO | Profile | |
Karthik CFA | Principal CFO | Profile | |
Andrew MBA | Chief Officer | Profile | |
MBA MD | CEO, CoFounder | Profile |
About Monopar Therapeutics Management Performance
The success or failure of an entity such as Monopar Therapeutics often depends on how effective the management is. Monopar Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Monopar management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Monopar management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.14) | (1.20) | |
Return On Capital Employed | (1.58) | (1.66) | |
Return On Assets | (1.14) | (1.20) | |
Return On Equity | (1.50) | (1.58) |
Monopar Therapeutics Workforce Analysis
Traditionally, organizations such as Monopar Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Monopar Therapeutics within its industry.Monopar Therapeutics Manpower Efficiency
Return on Monopar Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 933.6K | |
Net Loss Per Executive | 1.7M | |
Working Capital Per Employee | 619.5K | |
Working Capital Per Executive | 1.1M |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.